Standard BioTools (NASDAQ: LAB) furnishes preliminary 2025 results

Rhea-AI Filing Summary

Standard BioTools Inc. filed a Form 8-K to furnish a press release containing certain preliminary, unaudited financial results for the three months and fiscal year ended December 31, 2025. These figures are based on current expectations and may be adjusted after completion of the company’s year-end audit, financial closing procedures, and internal reviews.

The press release is included as Exhibit 99.1. The company notes that this information, including the exhibit, is being furnished rather than filed under the Securities Exchange Act, which limits its use for certain legal purposes.

false000116219400011621942026-01-082026-01-080001162194dei:FormerAddressMember2026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 8, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
50 Milk Street, 10th Floor Boston, Massachusetts 02109
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)
2 Tower Place, Suite 2000 South San Francisco, California 94080
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, $0.001 par value per share		LAB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On January 8, 2026, Standard BioTools Inc. (the "Company") issued a press release, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company's preliminary financial results are unaudited and based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information does not represent a comprehensive statement of the Company's financial results for the three months or fiscal year ended December 31, 2025 and remains subject to the completion of financial closing procedures and internal reviews.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Standard BioTools Inc., dated January 8, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Date:		January 8, 2026
	STANDARD BIOTOOLS INC.
	By:		/s/ Alex Kim
	Name:		Alex Kim
	Title:		Chief Financial Officer

FAQ

What did Standard BioTools (LAB) disclose in this Form 8-K?

Standard BioTools furnished a press release with preliminary, unaudited financial results for the three months and fiscal year ended December 31, 2025, as Exhibit 99.1.

Are Standard BioTools’ preliminary 2025 results audited?

No. The company states the preliminary results are unaudited, based on current expectations, and may change after completion of annual audit procedures and financial closing processes.

Which period do the preliminary financial results for Standard BioTools (LAB) cover?

The preliminary financial information in the press release covers the three months and fiscal year ended December 31, 2025.

How is the Exhibit 99.1 information treated under the Exchange Act?

The company states that the information in this report, including Exhibit 99.1, is being furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Who signed the Standard BioTools (LAB) Form 8-K related to the preliminary 2025 results?

The Form 8-K was signed on behalf of Standard BioTools Inc. by Alex Kim, Chief Financial Officer.

Where is Standard BioTools’ principal executive office located?

The company lists its principal executive offices at 50 Milk Street, 10th Floor, Boston, Massachusetts 02109.